 |
|
Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options
Inkeun Park, Jae Lyun Lee
Korean J Intern Med. 2020;35(4):834-853. Published online 2020 Jul 1 DOI: https://doi.org/10.3904/kjim.2020.204
|
|
Citations to this article as recorded by
 Real-World Utilization Patterns of Immune Checkpoint Inhibitors Based on the National Health Insurance Service Data in Korea
Eunji Kim, Yu-Seon Jung, Jongmin Lee, Dal Ri Nam, Seung-Hun You, Ju Won Lee, Sook Ryun Park, Ji Seon Oh, Ye-Jee Kim, Eun-Jung Jo, Nakyung Jeon, Won-Jung Jung, Sun-Young Jung
Clinical Therapeutics.2025; 47(10): 837. CrossRef Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis
Mairead Kearney, Liu Zhang, Elizabeth Hubscher, Mihaela Musat, Sharada Harricharan, Thomas Wilke
Future Oncology.2024; 20(16): 1123. CrossRef Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs
Xiaoyu Yang, Yunzhi Zhang, Jun Liu, Yougang Feng
Medicine.2024; 103(27): e38750. CrossRef Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis
Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Satoshi Nozaki, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Rika Banno, Hiroki Kubota, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Takahiro Yasui
International Journal of Clinical Oncology.2022; 27(1): 165. CrossRef Discovery of ASP5878: Synthesis and structure–activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity
Ikumi Kuriwaki, Minoru Kameda, Kazuhiko Iikubo, Hiroyuki Hisamichi, Yuichiro Kawamoto, Shigetoshi Kikuchi, Hiroyuki Moritomo, Tadashi Terasaka, Yoshinori Iwai, Atsushi Noda, Hiroshi Tomiyama, Aya Kikuchi, Masaaki Hirano
Bioorganic & Medicinal Chemistry.2022; 59: 116657. CrossRef Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure
Joo-Hwan Park, Inkeun Park, In-Ho Kim, Joon Young Hur, Inhwan Hwang, Chan Kim, Hyo-Jeong Kim, Chi Hoon Maeng, Kwonoh Park, Min-Young Lee, Hyo Jin Lee, Joo Young Jung, Bhumsuk Keam, Se Hoon Park, Jae Lyun Lee
Current Problems in Cancer.2022; 46(3): 100848. CrossRef Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?
Brian M. Russell, Leora Boussi, Joaquim Bellmunt
Drugs & Aging.2022; 39(4): 271. CrossRef Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
Giandomenico Roviello, Martina Catalano, Raffaella Santi, Matteo Santoni, Ilaria Camilla Galli, Andrea Amorosi, Wojciech Polom, Ugo De Giorgi, Gabriella Nesi
Frontiers in Oncology.2022;[Epub] CrossRef Frontiers in Bladder Cancer Genomic Research
Yi Li, Lihui Sun, Xiangyang Guo, Na Mo, Jinku Zhang, Chong Li
Frontiers in Oncology.2021;[Epub] CrossRef Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives
In-Ho Kim, Hyo-Jin Lee
International Journal of Molecular Sciences.2021; 22(13): 7201. CrossRef Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature
Felice Crocetto, Erika di Zazzo, Carlo Buonerba, Achille Aveta, Savio Domenico Pandolfo, Biagio Barone, Francesco Trama, Vincenzo Francesco Caputo, Luca Scafuri, Matteo Ferro, Vincenzo Cosimato, Ferdinando Fusco, Ciro Imbimbo, Giuseppe Di Lorenzo
Nutrients.2021; 13(11): 3750. CrossRef Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand
Alberto D’Angelo, Stefan Bagby, Ilaria Camilla Galli, Carlotta Bortoletti, Giandomenico Roviello
Expert Review of Clinical Pharmacology.2020; 13(10): 1139. CrossRef
|